Industry Insights
The global cholangiocarcinoma therapeutics market size will grow by USD 82.56 million during 2019-2023 at a CAGR of almost 6%. The growing usage of combination therapy and the need for drugs with minimal side-effects are some of the factors expected to drive market growth. This market report provides a detailed analysis of the market by type (intrahepatic cholangiocarcinoma and extrahepatic cholangiocarcinoma) and geography (Asia, Europe, North America, and ROW). Also, the report analyzes the market’s competitive landscape and offers information on several market vendors including Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Pfizer Inc., and Sanofi.
Cholangiocarcinoma is a rare and highly fatal cancer that starts in the cells of the bile duct. The disease is known to be caused by mutations in various types of genes. It is more common in people above 50 years of age.
Key Insights from Cholangiocarcinoma Therapeutics Market – Global Forecast 2019-2023
See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from this Cholangiocarcinoma Therapeutics Market report
The lack of effective therapeutics to control the last stages of diseases is compelling surgeons to choose surgery as a treatment option. However, vendors are coming up with a combination of chemotherapies to treat the disease. The growing usage of combination therapy is one of the critical factors that will drive the cholangiocarcinoma therapeutics market. This combination of drugs binds the strands of the cell’s deoxyribonucleic acid to abort the multiplication of cancer cells and hinders the production of both DNA and RNA to prevent cancer cells from repairing themselves.
Even though these chemotherapy drugs are serving the market, the side effects associated with these drugs are many and often severe. This substantial unmet need for drugs with minimal side-effects is encouraging vendors to support the development of novel therapies through massive investments in research activities. This will drive cholangiocarcinoma therapeutics market growth at a CAGR of almost 6% during the forecast period. Most of the novel therapy drugs such as biologics with the mechanism of actions such as PD-1 inhibitors and FGFR inhibitors have shown positive results in treating cholangiocarcinoma.
Industry Analysis
Quantitative Data
|
Qualitative Data
|
Type Insights
The type segment has been segregated into intrahepatic cholangiocarcinoma and extrahepatic cholangiocarcinoma. The intrahepatic cholangiocarcinoma segment accounted for the highest cholangiocarcinoma therapeutics market share in 2018. During the forecast period, this segment will grow at a faster pace than the overall market. The extrahepatic cholangiocarcinoma segment will grow at a slower pace than the overall market.
The intrahepatic cholangiocarcinoma segment will account for the highest share of the cholangiocarcinoma therapeutics market primarily because of the increasing incidence of the disease at the global level. The presence of various large and mid-sized pharmaceutical vendors with novel therapies in the last stages of clinical trials will also boost the growth of the market during the forecast period.
Regional Insights
North America accounted for the highest market share in 2018. Though the market’s growth in this region will be slower than the growth of the market in other regions, it will account for the largest cholangiocarcinoma therapeutics market share throughout the forecast period. The US is a key market for cholangiocarcinoma therapeutics in this region.
The high sales of approved therapeutics for the treatment of intrahepatic cholangiocarcinoma and extrahepatic cholangiocarcinoma is one of the primary reasons for the high growth of the cholangiocarcinoma therapeutics market in this region.
Top Cholangiocarcinoma Therapeutics Companies
The market is fairly concentrated. To help clients improve their position, this cholangiocarcinoma therapeutics market analysis report provides information on the competitive landscape and the products offered by various companies. Moreover, this cholangiocarcinoma therapeutics market research report also includes information on the upcoming trends and challenges that will influence market growth. This will help companies create strategies to make most of the upcoming growth opportunities.
The report offers a detailed analysis of leading cholangiocarcinoma therapeutics companies, including:
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd
- Pfizer Inc.
- Sanofi
Segments Covered in the Report
Cholangiocarcinoma therapeutics market by type
- Intrahepatic cholangiocarcinoma
- Extrahepatic cholangiocarcinoma
Cholangiocarcinoma therapeutics market by region
- Asia
- Europe
- North America
- ROW
Key Highlights of the Cholangiocarcinoma Therapeutics Market Forecast Report for the Period 2019-2023
- CAGR of the market during the forecast period 2019-2023
- Detailed information on factors that will accelerate the growth of the cholangiocarcinoma therapeutics market size during the next five years
- Precise estimation of the global cholangiocarcinoma therapeutics market size and its contribution to the parent market
- Accurate predictions on upcoming trends and changes in consumer behavior
- The growth of the cholangiocarcinoma therapeutics industry across Asia, Europe, North America, and ROW
- A thorough analysis of the market’s competitive landscape and detailed information on several vendors
-
Comprehensive details of factors that will challenge the growth of cholangiocarcinoma therapeutics companies
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch